A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL
概览
- 阶段
- 2 期
- 干预措施
- Ibrutinib
- 疾病 / 适应症
- CCND1 Positive
- 发起方
- M.D. Anderson Cancer Center
- 入组人数
- 113
- 试验地点
- 1
- 主要终点
- Incidence of toxicity, defined as grade 3 or higher non-hematologic toxicity, grade 3 neutropenia, grade 4 hematologic toxicity, inability to administer full schedule and dose, or inability to receive treatment day 1 of course 2
- 状态
- 进行中（未招募）
- 最后更新
- 2个月前
概览
简要总结
This phase II trial studies how well ibrutinib and rituximab work in treating patients with mantle cell lymphoma that has come back or has not responded to treatment or older patients with newly diagnosed mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them. Giving ibrutinib and rituximab may be an effective treatment for mantle cell lymphoma.
详细描述
PRIMARY OBJECTIVES: I. To evaluate the response rate of ibrutinib plus rituximab in patients with relapsed and/or refractory mantle cell lymphoma (MCL). II. To evaluate the safety and response rate of ibrutinib plus rituximab in elderly patients (\> 65) with newly-diagnosed, untreated MCL. SECONDARY OBJECTIVES: I. To further evaluate the toxicity profile of the combination of ibrutinib and rituximab in patients with relapsed and/or refractory MCL. II. To estimate the overall response rate (ORR); (partial response \[PR\] or better), the response duration (DOR), progression-free survival (PFS), time to progression (TTP) and overall survival (OS) in patients with relapsed and/or refractory MCL; clinical benefit response (CBR) = (minimal response \[MR\] + ORR) will also be evaluated. III. To estimate the response duration, PFS, time to progression (TTP), and OS in elderly patients (\> 65) with newly-diagnosed, untreated MCL. EXPLORATORY OBJECTIVES: I. To correlate detected gene mutations and changes in gene and/or protein expression with response to treatment. OUTLINE: Patients receive ibrutinib orally (PO) daily on days 1-28 and rituximab intravenously (IV) over 4-8 hours on days 1, 8, 15, and 22 of course 1; on day 1 of courses 3-8; and on day 1 of every other course for all subsequent courses. Treatment with rituximab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Courses with ibrutinib repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months thereafter.
研究者
入排标准
入选标准
- •Relapsed/refractory MCL: Confirmed diagnosis of mantle cell lymphoma with cluster of differentiation (CD)20 and cyclin D1 through cyclin D3 positivity in tissue biopsy
- •Relapsed/refractory MCL: Patient has relapsed and or refractory MCL and must have received at least one prior treatment regimen for their disease; patient with leukemia phase (peripheral blood involvement), leptomeningeal disease, cerebral spinal fluid (CSF) MCL, central nervous system (CNS) MCL, non-measurable disease, gastrointestinal (GI) MCL, or bone marrow (BM) MCL are also eligible
- •Relapsed/refractory MCL: Understand and voluntarily sign an Institutional Review Board (IRB)-approved informed consent form
- •Relapsed/refractory MCL: Patients with bone marrow or gastrointestinal (GI) only involvement are acceptable
- •Relapsed/refractory MCL: Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- •Relapsed/refractory MCL: Absolute neutrophil count (ANC) \>= 500/mm\^3; (patients who have bone marrow infiltration by MCL are eligible if their ANC is \>= 500/mm\^3 \[growth factor allowed\]; these patients should be discussed with either the principal investigator \[PI\] or Co-PI of the study for final approval)
- •Relapsed/refractory MCL: Platelet count \>= 30,000/mm\^3 (transfusion to reach platelet count allowed); (patients who have bone marrow infiltration by MCL are eligible if their platelet level is equal to or \> than 15,000/mm\^3; these patients should be discussed with either the PI or Co-PI of the study for final approval)
- •Relapsed/refractory MCL: Aspartate transaminase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine transaminase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) \< 2 x upper limit of normal or \< 5 x upper limit of normal if hepatic metastases are present
- •Relapsed/refractory MCL: Serum bilirubin \< 1.5 mg/dl
- •Relapsed/refractory MCL: Creatinine (Cr) clearance \>= 30 mL/min
排除标准
- •Relapsed/refractory MCL: Any serious medical condition that places the patient at unacceptable risk and/or would prevent the subject from signing the informed consent form; examples include but are not limited to, uncontrolled hypertension, uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, active infection, active hemorrhage, or psychiatric illness
- •Relapsed/refractory MCL: Pregnant or breast feeding females
- •Relapsed/refractory MCL: Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation
- •Relapsed/refractory MCL: The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patient's health and survival, than of the MCL, within the subsequent 6 months at the time of consent
- •Relapsed/refractory MCL: History of stroke or intracranial hemorrhage within 6 months prior to signing the consent
- •Relapsed/refractory MCL: Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months at the time of consent or any class 3 (moderate) or 4 (severe) cardiac disease defined by the New York Heart Association classification
- •Relapsed/refractory MCL: Significant screening electrocardiogram (ECG) abnormalities including left bundle branch block, 2nd degree atrioventricular (AV) block type II, 3rd degree block, bradycardia (\< 50 beats per minute \[bpm\]), or corrected QT (QTc) \> 500 msec
- •Relapsed/refractory MCL: Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
- •Relapsed/refractory MCL: Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, major surgery within 4 weeks or vaccination with live attenuated vaccines within 4 weeks of the first dose of study drug
- •Relapsed/refractory MCL: Prior treatment with ibrutinib
研究组 & 干预措施
Treatment (ibrutinib, rituximab)
Patients receive ibrutinib PO daily on days 1-28 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1; on day 1 of courses 3-8; and on day 1 of every other course for all subsequent courses. Treatment with rituximab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Courses with ibrutinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Ibrutinib
Treatment (ibrutinib, rituximab)
Patients receive ibrutinib PO daily on days 1-28 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1; on day 1 of courses 3-8; and on day 1 of every other course for all subsequent courses. Treatment with rituximab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Courses with ibrutinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis
Treatment (ibrutinib, rituximab)
Patients receive ibrutinib PO daily on days 1-28 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1; on day 1 of courses 3-8; and on day 1 of every other course for all subsequent courses. Treatment with rituximab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Courses with ibrutinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Rituximab
结局指标
主要结局
Incidence of toxicity, defined as grade 3 or higher non-hematologic toxicity, grade 3 neutropenia, grade 4 hematologic toxicity, inability to administer full schedule and dose, or inability to receive treatment day 1 of course 2
时间窗: Up to 4 weeks
Toxicity data will be summarized by frequency tables for all patients.
Overall response (complete response and partial response), assessed by the International Workshop Standardized Response Criteria for non-Hodgkin lymphoma
时间窗: Up to 8 weeks
Overall response will be monitored using the Bayesian stopping boundaries calculated based on beta-binomial distribution.
Incidence of grade 3 or higher non-hematologic toxicity, grade 3 neutropenia, grade 4 hematologic toxicity, inability to administer full schedule and dose, or inability to receive treatment day 1 of course 2 in newly diagnosed elderly patients
时间窗: Up to 4 weeks
Toxicity data will be summarized by frequency tables for all patients.
Overall response (complete response and partial response) in elderly patients with newly-diagnosed, untreated mantle cell lymphoma, assessed by the International Workshop Standardized Response Criteria for non-Hodgkin lymphoma
时间窗: Up to 8 weeks
Overall response will be monitored using the Bayesian stopping boundaries calculated based on beta-binomial distribution.
次要结局
- Progression-free survival(Up to 6 years)
- Time to progression(Up to 6 years)
- Overall survival(Up to 6 years)
- Duration of response in elderly patients with newly diagnosed, untreated mantle cell lymphoma(Up to 6 years)
- Overall survival in elderly patients with newly diagnosed, untreated mantle cell lymphoma(Up to 6 years)
- Time to progression in elderly patients with newly diagnosed, untreated mantle cell lymphoma(Up to 6 years)
- Clinical benefit response (minimal response + overall response rate),(Up to 6 years)
- Duration of response(Up to 6 years)
- Progression-free survival in elderly patients with newly diagnosed, untreated mantle cell lymphoma(Up to 6 years)